Literature DB >> 29507109

Epitope-Binding Characteristics for Risk versus Protective DRB1 Alleles for Visceral Leishmaniasis.

Toolika Singh1, Michaela Fakiola2, Joyce Oommen3, Akhil Pratap Singh1, Abhishek K Singh1, Noel Smith4, Jaya Chakravarty1, Shyam Sundar1, Jenefer M Blackwell5,3.   

Abstract

HLA-DRB1 is the major genetic risk factor for visceral leishmaniasis (VL). We used SNP2HLA to impute HLA-DRB1 alleles and SNPTEST to carry out association analyses in 889 human cases and 977 controls from India. NetMHCIIpan 2.1 was used to map epitopes and binding affinities across 49 Leishmania vaccine candidates, as well as across peptide epitopes captured from dendritic cells treated with crude Leishmania Ag and identified using mass spectrometry and alignment to amino acid sequences of a reference Leishmania genome. Cytokines were measured in peptide-stimulated whole blood from 26 cured VL cases and eight endemic healthy controls. HLA-DRB1*1501 and DRB1*1404/DRB1*1301 were the most significant protective and risk alleles, respectively, with specific residues at aa positions 11 and 13 unique to protective alleles. We observed greater peptide promiscuity in sequence motifs for 9-mer core epitopes predicted to bind to risk (*1404/*1301) compared with protective (*1501) DRB1 alleles. There was a higher frequency of basic amino acids in DRB1*1404/*1301-specific epitopes compared with hydrophobic and polar amino acids in DRB1*1501-specific epitopes at anchor residues pocket 4 and pocket 6, which interact with residues at DRB1 positions 11 and 13. Cured VL patients made variable, but robust, IFN-γ, TNF, and IL-10 responses to 20-mer peptides based on captured epitopes, with peptides based on DRB1*1501-captured epitopes resulting in a higher proportion (odds ratio 2.23, 95% confidence interval 1.17-4.25, p = 0.017) of patients with IFN-γ/IL-10 ratios > 2-fold compared with peptides based on DRB1*1301-captured epitopes. Our data provide insight into the molecular mechanisms underpinning the association of HLA-DRB1 alleles with risk versus protection in VL in humans.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29507109      PMCID: PMC5893436          DOI: 10.4049/jimmunol.1701764

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  72 in total

Review 1.  The wide diversity and complexity of peptides bound to class II MHC molecules.

Authors:  Anish Suri; Scott B Lovitch; Emil R Unanue
Journal:  Curr Opin Immunol       Date:  2005-11-28       Impact factor: 7.486

2.  Immune response to recombinant Leishmania infantum lipophosphoglycan 3 plus CpG oligodeoxynucleotides in BALB/c mice.

Authors:  L Pirdel; A Zavaran Hosseini
Journal:  Parasite Immunol       Date:  2017-03       Impact factor: 2.280

3.  Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis.

Authors:  S Sundar; S G Reed; S Sharma; A Mehrotra; H W Murray
Journal:  Am J Trop Med Hyg       Date:  1997-05       Impact factor: 2.345

4.  Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine.

Authors:  Rajiv Kumar; Yasuyuki Goto; Kamlesh Gidwani; Karen D Cowgill; Shyam Sundar; Steven G Reed
Journal:  Am J Trop Med Hyg       Date:  2010-05       Impact factor: 2.345

5.  Familial aggregation of Leishmania chagasi infection in northeastern Brazil.

Authors:  P H Cabello; A M Lima; E S Azevedo; H Krieger
Journal:  Am J Trop Med Hyg       Date:  1995-04       Impact factor: 2.345

6.  Splenic cytokine responses in Indian kala-azar before and after treatment.

Authors:  R T Kenney; D L Sacks; A A Gam; H W Murray; S Sundar
Journal:  J Infect Dis       Date:  1998-03       Impact factor: 5.226

7.  From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection.

Authors:  Carmel B Stober; Uta G Lange; Mark T M Roberts; Brian Gilmartin; Richard Francis; Renata Almeida; Christopher S Peacock; Sharon McCann; Jenefer M Blackwell
Journal:  Vaccine       Date:  2005-12-20       Impact factor: 3.641

8.  Genetic predisposition to self-curing infection with the protozoan Leishmania chagasi: a genomewide scan.

Authors:  Selma M B Jeronimo; Priya Duggal; Nicholas A Ettinger; Eliana T Nascimento; Gloria R Monteiro; Angela P Cabral; Nubia N Pontes; Henio G Lacerda; Paula V Queiroz; Carlos E M Gomes; Richard D Pearson; Jenefer M Blackwell; Terri H Beaty; Mary E Wilson
Journal:  J Infect Dis       Date:  2007-09-13       Impact factor: 5.226

Review 9.  Whole blood assay and visceral leishmaniasis: Challenges and promises.

Authors:  Om Prakash Singh; Shyam Sundar
Journal:  Immunobiology       Date:  2014-01-31       Impact factor: 3.144

10.  Association of HLA-DRB1-restricted CD4⁺ T cell responses with HIV immune control.

Authors:  Srinika Ranasinghe; Sam Cutler; Isaiah Davis; Richard Lu; Damien Z Soghoian; Ying Qi; John Sidney; Gregory Kranias; Michael D Flanders; Madelene Lindqvist; Bjorn Kuhl; Galit Alter; Steven G Deeks; Bruce D Walker; Xiaojiang Gao; Alessandro Sette; Mary Carrington; Hendrik Streeck
Journal:  Nat Med       Date:  2013-06-23       Impact factor: 53.440

View more
  5 in total

1.  HLA-DR Class II expression on myeloid and lymphoid cells in relation to HLA-DRB1 as a genetic risk factor for visceral leishmaniasis.

Authors:  Bhawana Singh; Michaela Fakiola; Medhavi Sudarshan; Joyce Oommen; Siddharth Sankar Singh; Shyam Sundar; Jenefer M Blackwell
Journal:  Immunology       Date:  2018-11-22       Impact factor: 7.397

Review 2.  Genetics, Transcriptomics and Meta-Taxonomics in Visceral Leishmaniasis.

Authors:  Jenefer M Blackwell; Michaela Fakiola; Om Prakash Singh
Journal:  Front Cell Infect Microbiol       Date:  2020-11-25       Impact factor: 5.293

3.  Spatial and Temporal Variability of Visceral Leishmaniasis in Colombia, 2007 to 2018.

Authors:  Adriana Castillo-Castañeda; Giovanny Herrera; Martha S Ayala; Patricia Fuya; Juan David Ramírez
Journal:  Am J Trop Med Hyg       Date:  2021-07-07       Impact factor: 3.707

4.  An immunoinformatic approach driven by experimental proteomics: in silico design of a subunit candidate vaccine targeting secretory proteins of Leishmania donovani amastigotes.

Authors:  Md Anik Ashfaq Khan; Jenifar Quaiyum Ami; Khaledul Faisal; Rajashree Chowdhury; Prakash Ghosh; Faria Hossain; Ahmed Abd El Wahed; Dinesh Mondal
Journal:  Parasit Vectors       Date:  2020-04-15       Impact factor: 3.876

5.  HLA-DRB1 Alleles Associated with Lower Leishmaniasis Susceptibility Share Common Amino Acid Polymorphisms and Epitope Binding Repertoires.

Authors:  Nicky de Vrij; Pieter Meysman; Sofie Gielis; Wim Adriaensen; Kris Laukens; Bart Cuypers
Journal:  Vaccines (Basel)       Date:  2021-03-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.